New FDA Guidance and Labeling Changes Affecting PneumoLiner, the Only 510(k)-Cleared Containment Device Reports Olympus

New FDA Draft Guidance Now Mandates Surgeons Use Power Morcellation Only with an Approved Containment System for Gynecological Tissue

In a recent press release, the FDA states about the PneumoLiner: “While the device itself remains unchanged since its prior marketing authorization, today’s clearance updates the labeling for this device to better define the appropriate patient population for the safe and effective use of this device, including stating that the device should only be used in women who have fibroids if they are pre-menopausal and under 50 years old.”

The FDA safety communication update on power morcellation includes additional recommendations including:

  • That health care providers use tissue containment systems when using laparoscopic power morcellators, and that they ensure the laparoscopic power morcellator and tissue containment system are compatible, legally marketed laparoscopic power morcellation containment systems intended to isolate and contain tissue that is considered benign.
  • As demonstrated in testing, use of a containment system confines morcellated tissue within the containment system, which may prevent the peritoneal spread of cancerous tissue.
  • Laparoscopic power morcellation (with a compatible containment system) should only be used in the appropriate patient population:
    • women without uterine fibroids undergoing hysterectomy
    • and women with fibroids, provided they are pre-menopausal and under age 50 with fibroids (with no suspicion of malignancy).

The leading gynecological laparoscopy association, AAGL, immediately endorsed the FDA’s guidance, with the following statement from its President, Jubilee Brown, MD: “The specification of age-related risk is consistent with scientific data and reflects clinical experience allowing power morcellation in low- risk patients when performed with a containment system compatible with the laparoscopic power morcellator. Utility of a contained tissue extraction system in a low- risk population appears to mitigate the risk of poor outcomes that may be associated with uncontained power morcellation.” The AAGL encouraged its members to submit electronic comments to the FDA’s Federal Register.

These modifications clarify power morcellation usage guidelines along with containment in appropriately selected patients. Further, the FDA clarifies the appropriate patient population by eliminating the ambiguous term “peri-menopausal” from the contraindications, and adds an easier-to-follow age restriction.

Medical Device News Magazinehttps://infomeddnews.com
Our publication is dedicated to bringing our readers the latest medical device news. We are proud to boast that our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall purpose and objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

OTHER NEWS

"Receiving this first FDA clearance for our retinal camera is not just a milestone, it's a leap forward in our quest to safeguard the vision of millions," said Dr. Patrick Sauvageau, optometrist, CEO, and co-founder of Zilia. "We're now focused on obtaining De Novo classification for ocular oximetry, a breakthrough biomarker that promises to revolutionize how we diagnose and manage a variety of ocular conditions."
The recent FDA clearances included Brainomix 360 e-CTP and Brainomix 360 e-MRI, both software modules that can support thrombolysis and thrombectomy treatment decisions, particularly for late-window patients who present to hospital more than 6-12 hours after stroke onset.
IONIC Health’s 510(k)-pending nCommand Lite technology is designed to include vendor-agnostic remote scanning capabilities. This strategic collaboration’s goal is to enable GE HealthCare to provide a multi-vendor, multi-modality remote scanning solution to healthcare systems and patients around the globe.
Silmitasertib works by inhibiting CK2 protein kinase, which have implicated in regulation of several signaling pathways that are important for innate immune responses. CK2 modulates inflammatory pathways, including NF-κB, PI3K–Akt–mTOR, and JAK–STAT.
"This is the culmination of years of research and development to deliver a medical device that helps improve the lives of patients suffering from spinal stenosis. Our recent move to larger premises in the Research Park at FAU will allow us to train our surgical and distribution partners to become increasingly competitive in the spinal implant device market,” said Peter Harris, founder and CEO of FloSpine.

By using this website you agree to accept Medical Device News Magazine Privacy Policy